Gadolinium-based contrast agents: A comprehensive risk assessment.

Published

Journal Article (Review)

Gadolinium-based contrast agents (GBCAs) have been used in magnetic resonance imaging (MRI) since the 1980s and are now administered in up to 35% of all MRI examinations. While GBCAs were initially felt to carry minimal risk, the subsequent identification of GBCAs as the key etiologic factor in the development of nephrogenic systemic fibrosis (NSF) has raised concerns about the broader health impacts of gadolinium exposure. Clinicians, radiologists, and patients should be aware of the most up-to-date data pertaining to the risks of GBCA administration. Specific issues covered in this review article include immediate adverse reactions; pregnancy and lactation; and gadolinium deposition and toxicity, with a special focus on NSF. Practice recommendations based on the presented data, as well as current professional society guidelines, are provided for each section. LEVEL OF EVIDENCE: 1 Technical Efficacy: Stage 5 J. MAGN. RESON. IMAGING 2017;46:338-353.

Full Text

Duke Authors

Cited Authors

  • Fraum, TJ; Ludwig, DR; Bashir, MR; Fowler, KJ

Published Date

  • August 2017

Published In

Volume / Issue

  • 46 / 2

Start / End Page

  • 338 - 353

PubMed ID

  • 28083913

Pubmed Central ID

  • 28083913

Electronic International Standard Serial Number (EISSN)

  • 1522-2586

Digital Object Identifier (DOI)

  • 10.1002/jmri.25625

Language

  • eng

Conference Location

  • United States